CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-23 | Savill Corrine Chief Business Officer | Option exercise 10b5-1 | +21,316 | $4.30 | $92K | 187,306 |
| 2024-01-23 | Savill Corrine Chief Business Officer | Sale 10b5-1 | −21,316 | $12.46 | $266K | 165,990 |
| 2024-01-23 | Savill Corrine Chief Business Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −21,316 | 13,997 | ||
| 2024-01-22 | Savill Corrine Chief Business Officer | Option exercise 10b5-1 | +14,559 | $4.30 | $63K | 184,674 |
| 2024-01-22 | Savill Corrine Chief Business Officer | Sale 10b5-1 | −14,559 | $12.18 | $177K | 170,115 |
| 2024-01-22 | Savill Corrine Chief Business Officer | Sale 10b5-1 | −4,125 | $12.02 | $50K | 165,990 |
| 2024-01-22 | Savill Corrine Chief Business Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −14,559 | 35,313 | ||
| 2023-12-26 | AHMED NADIM President and CEO | Sale | −4,272 | $9.24 | $39K | 111,550 |
| 2023-12-21 | Jones Jeffrey Alan Chief Medical Officer | Sale | −1,860 | $8.50 | $16K | 56,191 |
| 2023-12-21 | SUMER JACQUELYN L Chief Legal Officer | Sale | −1,400 | $8.50 | $12K | 44,133 |
| 2023-12-21 | Trigilio Jeffrey Chief Financial Officer | Sale | −1,920 | $8.50 | $16K | 83,919 |
| 2023-12-21 | Michaelson Jennifer Chief Scientific Officer | Sale | −1,145 | $8.50 | $10K | 87,582 |
| 2023-12-18 | Michaelson Jennifer Chief Scientific Officer | Sale | −238 | $8.22 | $2K | 88,727 |
| 2023-12-18 | Jones Jeffrey Alan Chief Medical Officer | Sale | −386 | $8.22 | $3K | 58,051 |
| 2023-12-18 | SUMER JACQUELYN L Chief Legal Officer | Sale | −290 | $8.22 | $2K | 45,533 |
| 2023-12-18 | Trigilio Jeffrey Chief Financial Officer | Sale | −398 | $8.22 | $3K | 85,839 |
| 2023-12-12 | Trigilio Jeffrey Chief Financial Officer | Sale | −1,926 | $7.81 | $15K | 86,237 |
| 2023-12-12 | Michaelson Jennifer Chief Scientific Officer | Sale | −1,068 | $7.81 | $8K | 88,965 |
| 2023-06-30 | Trigilio Jeffrey Chief Financial Officer | Grant or award | +2,340 | $9.08 | $21K | 88,163 |
| 2023-06-28 | AHMED NADIM President and CEO | Sale | −759 | $11.40 | $9K | 115,822 |
Page 8 of 23 · 446 trades